BREYANZI 1.1 à 70 × 1 000 000 cells/ml / 1.1 à 70 × 1 000 000 cells/ml, dispersion for infusion 4 bottles of 4.6 ml
Active ingredients: LISOCABTAGÈNE MARALEUCEL
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Dispersion and dispersion for infusion4 bottles of 4.6 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BREYANZI 1,1 à 70 × 1 000 000 cellules/ml / 1,1 à 70 × 1 000 000 cellules/ml, dispersion pour perfusion
- Pharmaceutical form
- dispersion et dispersion pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 à 4 flacons copolymère de cyclooléfines de 4,6 ml de chaque composant cellulaire
- Marketing authorisation holder
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Sept 2023
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
61038695CIP75508953CIP133400955089537Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LISOCABTAGÈNE MARALEUCELdispersion cellulaire CD4+ | 1,1 à 70 × 1 000 000 lymphocytes T viables CAR positifs · 1 mL de dispersion | SA |
| LISOCABTAGÈNE MARALEUCELdispersion cellulaire CD8+ | 1,1 à 70 × 1 000 000 lymphocytes T viables CAR positifs · 1 mL de dispersion | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.